Thus, we believe that Gal-3 may be an effective biomarker for the prediction of disease activity and cytokine release syndrome, including MAS, in AOSD and may provide useful information concerning disease activity and inflammatory cytokine cascades in patients with AOSD. This evidence concerns the gene LGALS3 and macrophage activation syndrome.